Nucleosides and Nucleotides as Antitumor and Antiviral Agents

  • Chung K. Chu
  • David C. Baker

Table of contents

  1. Front Matter
    Pages i-x
  2. Akira Matsuda, Atsushi Azuma, Yuki Nakajima, Kenji Takenuki, Akihito Dan, Tomoharu Iino et al.
    Pages 1-22
  3. Hiromichi Tanaka, Hiroyuki Hayakawa, Tadashi Miyasaka
    Pages 23-53
  4. Ernest J. Prisbe, Hans Maag, Julien P. H. Verheyden, Robert M. Rydzewski
    Pages 101-113
  5. Morris J. Robins, Stanislaw F. Wnuk, Khairuzzaman B. Mullah, N. Kent Dalley, Ronald T. Borchardt, Younha Lee et al.
    Pages 115-126
  6. Stewart W. Schneller, Xing Chen, Suhaib M. Siddiqi
    Pages 141-158
  7. J. Warren Beach, Lak S. Jeong, Hea O. Kim, S. Nampalli, K. Shanmuganathan, Chung K. Chu
    Pages 219-243
  8. Victor E. Marquez, Benjamin B. Lim, Joseph J. Barchi Jr., Marc C. Nicklaus
    Pages 265-284
  9. Patrick Van Roey, Chung K. Chu
    Pages 285-302
  10. Françoise Debart, Carole Chaix, Bernard Rayner, Jean-Louis Imbach
    Pages 303-310
  11. Back Matter
    Pages 325-336

About this book

Introduction

Due to the worldwide epidemic of acquired immunodeficiency syndrome (AIDS), the past ten years have witnessed a flurry of activity in the chemotherapy of viral diseases. Unprecedented scientific efforts have been made by scientists and clinicians to combat infections of human immunodeficiency virus (HIY), the causative agent. Looking back over the past ten years, we have made remarkable progress toward the treatment of the viral disease: isolation of HIV only two years after the identification of the disease, plus major strides in the areas of the molecular biology and virology of the retrovirus, etc. More remarkably, the discovery of the chemotherapeutic agent AZT (Retrovir) was made within two years after the isolation and identification of the virus, followed by unprecedented drug development efforts to culminate in the FDA approval of AZT in twenty-three months, which was a record-breaking time for approval of any drug for a major disease. The last six to seven years have particularly been an exciting and productive period for nucleoside chemists. Since the activity of AZI' was established in 1985, nucleoside chemists have had golden opportunities to discover additional anti-HIV nucleosipes, which are hoped to be less toxic and more effective than AZT, and the opportunity continues. As we all are aware, AZT possesses extremely potent anti-HIY activity, and no other nucleoside or non­ nucleoside has surpassed the potency of AZT in vitro.

Keywords

AIDS HIV biology cancer chemistry chemotherapy development diseases drug drug development molecular biology research therapy virology virus

Editors and affiliations

  • Chung K. Chu
    • 1
  • David C. Baker
    • 2
  1. 1.The University of GeorgiaAthensGeorgia
  2. 2.The University of TennesseeKnoxvilleUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-2824-1
  • Copyright Information Plenum Press, New York 1993
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6221-0
  • Online ISBN 978-1-4615-2824-1
  • About this book